Clinical trial · Interventional
Oral Curcumin for Radiation Dermatitis
Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine whether curcumin, an ingredient of some foods, can prevent or reduce the severity of skin reactions (dermatitis) caused by radiation therapy. Dermatitis is a common side effect of radiation treatment, but few effective treatments have been developed for it. Curcumin is a natural compound found in both turmeric and curry powder. It has been used for centuries as a spice (curry), a food coloring and as a food preservative. Curcumin is non-toxic and has been found to enhance the functions of normal tissues..
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation-induced Dermatitis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- curcumin
- description
- 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
- interventionNames
- Drug: Curcumin
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Mean Radiation Dermatitis Severity Score
- timeFrame
- 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion Criteria: * a diagnosis of non-inflammatory breast adenocarcinoma (including in situ and bilateral) * scheduled to begin radiotherapy without concurrent chemotherapy; concurrent hormone or Herceptin® (trastuzumab)treatment is okay * can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment * can have had breast reconstruction * scheduled to receive 25-35 radiation treatment sessions (1 session per day) using standard irradiation fractionation (1.8-2.0 Gy per sessions) OR 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session)(100, 101). * able to swallow medication. * three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study * able to understand English Exclusion Criteria: * inflammatory breast cancer * previous radiation therapy to the breast or chest * concurrent chemotherapy treatment * concurrent treatment with anti-coagulants (e.g., coumadin®, warfarin®), or anti-EGFR (human epidermal growth factor receptor) drugs (e.g. Iressa® (gefitinib), Erbitux® (cetuximab, C225); aspirin is allowed * known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) * collagen vascular disease, unhealed surgical sites, or breast infections
References
Publications (0)
Data not yet available